Phase 1/2 Trial Testing Combo of Bria-IMT and Immune Checkpoint Inhibitors Begins Dosing Breast Cancer Patients
News
BriaCell Therapeutics has started patient dosing in a Phase 1/2a clinical trial testing its immunotherapy candidate Bria-IMT — used in combination with the immune checkpoint inhibitors Keytruda (pembrolizumab) or Yervoy (ipilimumab) — ... Read more